業績（2024年度）

英文原著

  1. Asonuma K, Ozeki K, Yamazaki H, Okabayashi S, Okano S, Ozaki R, Nishimata N, Kiyohara H, Ichinari N, Kobayashi T, Yamada M, Matsubayashi M, Yokoyama Y, Arimitsu S, Umeno J, Munetomo Y, Andoh A, Shinzaki S.
    Immunomodulators after the discontinuation of anti-tumor necrosis factor-alpha antibody treatment and relapse in ulcerative colitis: A multicenter cohort study.
    J Gastroentero Hepatol. 2024 January;39(1):66-73
  2. Chen J Oshima T, Tomita T, Fukui H, Shinzaki S.
    Regulatory T cells Are Increased and Crrelate With Mast Cells in Eosinophilic Esophagitis
    J Neurogastroenterol Motil 2024 January;30(1):29-37
  3. Nakajima N, Takeuchi T, Hokari R, Narimatsu K, Iijima K, Koizumi S, Kasugai K, Ebi M, Nagahara A, Takeda T, Tomita T, Shinzaki S, Mizukami K, Murakami K, Yagi N, Mukai R, Okumura T, Tanabe H, Tanaka K, Iwamoto J, Irisawa A, Fukushi K, Kataoka H, Nishie H, Fujiwara Y, Otani K, Handa O, Maruyama Y, Uraoka T, Hosaka H, Furuta T, Takagi T, Nakamura M, Nyumura Y, Hakoda A, Sugawara N, Iwatubo T, Ota K, Kawaguchi S, Higuchi K, Nishikawa H.
    Background factors of idiopathic peptic ulcers and optimal treatment methods; a multicenter retrospective Japanise study.
    J Clin Biochem Nutr 2024 January;74(1):82-89
  4. Arase N, Sasaoka Y, Narita J, Kiyohara E, Hashimoto K, Shinzaki S, Nojima S, Takagi J, Fujimoto M.
    Anti-α6β4 integrin autoantibodies inhibit the binding of laminins to α6β4 integrin in patients with pemphigoid and affect the gastrointestinal tract. J Eur Acad Dermatol Venereol 2024 Feburary;38(2):404-412
  5. Horio Y, Uchino M, Igeta M, Nagano K, Kusunoki K, Kuwahara R, Sato T, Shinzaki S, Ikeuchi H.
    The Comprehensive Complication Index in Ulcerative Colitis: A Comparison with the Clavien-Dindo Classification.
    Inflamm Intest Dis 2024 March;9(1):85-95
  6. Akiyama S, Yokoyama K, Yagi S, Shinzaki S, Tsuruta K, Yoshioka S, Sako M, Shimizu H, Kobayashi M, Sakurai T, Nomura K, Shibuya T, Takahara M, Hiraoka S, Sugai K, Yanai S, Yoshida A, Koroku M, Omori T, Saruta M, Matsumoto T, Okamoto R, Tsuchiya K, Fujii T.
    Efficacy and safety of filgotinib for ulcerative colitis: A real-world multicenter retrospective study in Japan.
    Aliment Pharmacol Ther 2024 June;59(11):1413-1424
  7. Soichi Yagi,Hirokazu Fukui,Maiko Ikenouchi,Tetsuya Shiraishi,Koji Kaku,Midori Wakita,Yasuhiro Takagi,Toshiyuki Sato,Mikio Kawai,Koji Kamikozuru,Yoko Yokoyama,Tetsuya Takagawa,Toshihiko Tomita and Shinichiro Shinzaki.
    Continuous Treatment with Tofacitinib but Not Filgotinib Is Effective in Non-Responders with Active Ulcerative Colitis: A Propensity Score-Matching Analysis.
    Journal of Clinical Medicine 2025 January;14(1):doi: 10.3390/jcm14010217.

英文総説

  1. Ihara Eikichi, Manabe Noriaki, Ohkubo Hidenori, Ogasawara Naotaka, Ogino Haruei, Kakimoto Kazuki, Kanazawa Motoyori, Kawahara Hidejiro, Kusano Chika, Kuribayashi Shiko, Sawada Akinari, Takagi Tomohisa, Takano Syota, Tomita Toshihiko, Noake Toshihiro, Hojo Mariko, Hokari Ryota, Masaoka Tatsuhiro, Machida Tomohiko, Misawa Noboru, Mishima Yoshiyuki, Yajima Hiroshi, Yamamoto Sayuri, Yamawaki Hiroshi, Abe Tatsuya, Araki Yasumi, Kasugai Kunio, Kamiya Takeshi, Torii Akira, Nakajima Atsushi, Nakada Koji, Fukudo Shin, Fujiwara Yasuhiro, Miwa Hiroto, Kataoka Hiromi, Nagahara Akihito, Higuchi Kazuhide.
    Evidence-Based Clinical Guidelines for Chronic Constipation 2023.
    Digestion 2024 August;106(1):62-89

邦文総説

  1. 富田寿彦、新﨑信一郎
    治療05 Q136.便秘治療におけるMgO,刺激性下剤のエビデンスは？①、治療06 Q137.便秘治療におけるMgO,刺激性下剤のエビデンスは？②
    これだけは読んでおきたい！消化器医のための重要論文209篇〈機能性消化管障害編〉2024;Jly;第一版:142-143
  2. 髙川哲也、新﨑信一郎
    IBDにおける免疫異常と分子標的薬の使い分けのrationale
    臨床消化器内科 2024;Oct;39(2):134-139

業績（2022-2023年度）

英文原著

  1. Yoshimoto T, Oshima T, Fukada T, Imamura N, Nakanishi T, Ebisutani N, Morishita D, Mieno M, Nakai K, Sei H, Kitayama Y, Eda H, Okugawa T, Tomita T, Fukui H, Shinzaki S.
    Pegfilgrastim for the management of neutropenia during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer patients. Int J Clin Oncol. 2023 Dec 8. Online ahead of print.
  2. Wong SY, Wellens J, Helmus D, Marlow L, Brann S, Martinez Pazos V, Weinberg A, Moran HR, McGregor C, Vermeire S, Watanabe K, Kamikozuru K, Ahuja V, Vermani S, Lindsay JO, Kingston A, Dutta U, Kaur H, Silverberg MS, Milgrom R, Chien Ng S, Mak JWY, Cadwell K, Thompson C, Colombel JF, Satsangi J; ICARUS-IBD Consortium.
    Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium.
    Inflamm Bowel Dis. 2023 Nov 2;29(11):1693–1705
  3. Hirai M, Yanai S, Kunisaki R, Nishio M, Watanabe K, Sato T, Ishihara S, Anzai H, Hisabe T, Yasukawa S, Maeda Y, Takishima K, Ohno A, Shiga H, Uraoka T, Itoi Y, Ogata H, Takabayashi K, Yoshida N, Saito Y, Takamaru H, Kawasaki K, Esaki M, Tsuruoka N, Hisamatsu T, Matsumoto T.
    Effectiveness of endoscopic resection for colorectal neoplasms in ulcerative colitis: a multicenter registration study.
    Gastrointest Endosc. 2023 Nov;98(5):806-812.
  4. Watanabe K, Nojima M, Nakase H, Sato T, Matsuura M, Aoyama N, Kobayashi T, Sakuraba H, Nishishita M, Yokoyama K, Esaki M, Hirai F, Nagahori M, Nanjo S, Omori T, Tanida S, Yokoyama Y, Moriya K, Maemoto A, Handa O, Ohmiya N, Tsuchiya K, Shinzaki S, Kato S, Uraoka T, Tanaka H, Takatsu N, Nishida A, Umeno J, Nakamura M, Mishima Y, Fujiya M, Tsuchida K, Hiraoka S, Okabe M, Toyonaga T, Matsuoka K, Andoh A, Hirota Y, Hisamatsu T; J-COMBAT study group.
    Trajectory analyses to identify persistently low responders to COVID-19 vaccination in patients with inflammatory bowel disease: a prospective multicentre controlled study, J-COMBAT.
    J Gastroenterol. 2023 Oct;58;(10):1015-1029.
  5. Yamamoto T, Nakase H, Watanabe K, Shinzaki S, Takatsu N, Fujii T, Okamoto R, Matsuoka K, Yamada A, Kunisaki R, Matsuura M, Shiga H, Bamba S, Mikami Y, Shimoyama T, Motoya S, Torisu T, Kobayashi T, Ohmiya N, Saruta M, Matsuda K, Matsumoto T, Maemoto A, Murata Y, Yoshigoe S, Nagasaka S, Yajima T, Hisamatsu T.
    Diagnosis and Clinical Features of Perianal Lesions in Newly Diagnosed Crohn’s Disease: Subgroup Analysis from Inception Cohort Registry Study of Patients with Crohn’s Disease (iCREST-CD).
    J Crohns Colitis. 2023 Aug 21;17(8):1193-1206.
  6. Tomita T, Fukui H, Okugawa T, Nakanishi T, Mieno M, Nakai K, Eda H, Kitayama Y, Oshima T, Shinzaki S, Miwa H.
    Effect of Bifidobacterium bifidum G9-1 on the Intestinal Environment and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-like Symptoms in Patients with Quiescent Crohn's Disease: A Prospective Pilot Study.
    J Clin Med. 2023 May 9;12(10):3368
  7. Yoshihara T, Shinzaki S, Iijima H, Tsujii Y, Hayashi Y, Takehara T.
    Combination therapy of ustekinumab and immunomodulator for inflammatory bowel disease concerns about the different results obseved between two meta-analyses.
    J Gastroenterol Hepatol. 2023 May;38(5):830-832
  8. Sato T, Uchino M, Takeuchi J, Fujihira Y, Shimizu K, Yokoyama K, Yagi S, Kaku K, Takashima Y, Ikenouchi M, Kojima K, Kawai M, Nagase K, Kamikozuru K, Yokoyama Y, Takagawa T, Ikeuchi H, Watanabe K, Shinzaki S.
    Short-term clinical evaluation of teduglutide for patients with Crohn’s disease on home parenteral support for postoperative short bowel syndrome with intestinal failure.
    Clin Nutr. 2023 May;42(5):722-731
  9. Tomita T, Fukui H, Morishita D, Maeda A, Makizaki Y, Tanaka Y, Ohno H, Oshima T, Miwa H. Diarrhea-predominant Irritable Bowel Syndrome-like Symptoms in Patients With Quiescent Crohn’s Disease:Comprehensive Analysis of Clinical Features and Intestinal Environment Including the Gut Microbiome, Organic Acids, and Intestinal Permeability.
    J Neurogastroenterol Motil. 2023 Jan 30;29(1):102-112.
  10. Tomita T, Fukui H, Morishita D, Mori S, Oshima T, Shinzaki S, Miwa H.
    Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.
    J Clin Med. 2022 Nov 22;11(23):6882.
  11. Matsuoka K, Fujii T, Okamoto R, Yamada A, Kunisaski R, Matsuura M, Watanabe K, Shiga H, Takatsu N, Bamba S, Mikami Y, Yamamoto T, Shimoyama T, Motoya S, Trisu T, kobayashi T, Ohmiya N, Saruta M, Matsuda K, Matsumoto T, Nakase H, Maemoto A, Shinzaki S, Murata Y, Yoshigoe S, Sasaki A, Yajima T, Hisamatsu T.
    Characteristics of adult patients newly diagnosed with Crohn’s disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn’s disease in Japan (iCREST-CD).
    J Gastroenterol. 2022 Nov;57(11):867-878

英文総説

  1. Shinichiro S, Sato T, Fukui H.
    Antidiabetic drugs for IBD: a long but promising road ahead for drug repositioning to target intestinal inflammation.
    J Gastroenterol. 2023 Jun;58(6):598-599

邦文総説

  1. 富田寿彦、福井広一、三輪洋人、新﨑信一郎
    特集　管理栄養士も知っておきたい 機能性消化管障害の症状とその管理
    機能性ディスペプシア─その症状と対応
    臨床栄養2023;vol.143,No.5:639-644
  2. 富田寿彦、福井広一、新﨑信一郎
    便秘編 ①便秘を知る 原因別・便秘の種類
    薬局2023;vol.74,No.6:1078-1081
  3. 髙川哲也、新﨑信一郎
    【最新医療に向け新薬の標的を知る】IL-23p19を知る
    消化器病サイエンス2023;Mar;7(1):24-27
  4. 福井広一、富田寿彦、大島忠之、新﨑信一郎
    【鋸歯状病変関連の早期大腸癌】鋸歯状病と腸内細菌の関係
    胃と腸 2023;Feb;58(2):204-206
  5. 大島忠之、 新﨑信一郎
    【PPIの功罪(PCABを含む)】機能性ディスペプシア(FD)に対するPPI治療の注意点
    日本内科学会雑誌 2023;Jan;112(1):25-31